021-51111890
购物车（）
sales@molnova.cn
Ladiratuzumab
CAS No. 1629760-28-6
Ladiratuzumab ( —— )
产品货号. M36886 CAS No. 1629760-28-6
Ladiratuzumab (hLIV22) 是一种抗 LIV-1/ZIP6 的人源化单克隆抗体。Ladiratuzumab 与微管干扰剂 MMAE (HY-15162) 偶联，能够合成一种抗体-活性分子偶联物 (ADC) SGN-LIV1A。Ladiratuzumab 可用于乳腺癌的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥3398 | 有现货 |
|
| 5MG | ￥4344 | 有现货 |
|
| 10MG | ￥7041 | 有现货 |
|
| 25MG | ￥10088 | 有现货 |
|
| 50MG | ￥13529 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Ladiratuzumab
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Ladiratuzumab (hLIV22) 是一种抗 LIV-1/ZIP6 的人源化单克隆抗体。Ladiratuzumab 与微管干扰剂 MMAE (HY-15162) 偶联，能够合成一种抗体-活性分子偶联物 (ADC) SGN-LIV1A。Ladiratuzumab 可用于乳腺癌的研究。
-
产品描述Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number1629760-28-6
-
分子量
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. ?
产品手册
关联产品
-
AD 01
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
-
ZLDI-8
ZLDI-8 是 Notch 激活/裂解酶 ADAM-17 的抑制剂，可抑制 Notch 蛋白的裂解。ZLDI-8；它抑制NOTCH蛋白的裂解，从而降低促生存/抗凋亡和EMT相关蛋白的表达。
-
Biotinyl-MCH (salmon...
Biotinyl-MCH (salmon)
